Wuhan Hiteck Biological Pharma Co Ltd Working Capital to Net Assets Ratio
Wuhan Hiteck Biological Pharma Co Ltd working capital to net assets ratio. Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Working Capital to Net Assets ratio of 45.4% as of June 2026. Working capital of CN¥948.94 Million (current assets of CN¥1.23 Billion minus current liabilities of CN¥282.04 Million) is measured against net assets of CN¥2.09 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Wuhan Hiteck Biological Pharma Co Ltd (2013–2025)
Working capital to net assets ratio of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2025. This chart shows how Wuhan Hiteck Biological Pharma Co Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of June 2026, the ratio stands at 45.4%, reflecting working capital of CN¥948.94 Million against net assets of CN¥2.09 Billion CNY. See 300683 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Wuhan Hiteck Biological Pharma Co Ltd Working Capital to Net Assets Ratio by Year (2013–2025)
Wuhan Hiteck Biological Pharma Co Ltd working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Wuhan Hiteck Biological Pharma Co Ltd assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 42.5% | CN¥921.02 Million | CN¥2.17 Billion | CN¥1.23 Billion | CN¥308.85 Million | ▲ +3.3 pp |
| 2024 | 39.1% | CN¥943.07 Million | CN¥2.41 Billion | CN¥1.31 Billion | CN¥363.26 Million | ▼ -6.7 pp |
| 2023 | 45.8% | CN¥1.14 Billion | CN¥2.50 Billion | CN¥1.49 Billion | CN¥346.15 Million | ▼ -3.9 pp |
| 2022 | 49.6% | CN¥1.16 Billion | CN¥2.34 Billion | CN¥1.44 Billion | CN¥284.73 Million | ▼ -7.3 pp |
| 2021 | 56.9% | CN¥1.33 Billion | CN¥2.34 Billion | CN¥1.58 Billion | CN¥249.25 Million | ▲ +1.2 pp |
| 2020 | 55.7% | CN¥960.99 Million | CN¥1.72 Billion | CN¥1.33 Billion | CN¥367.31 Million | ▼ -5.8 pp |
| 2019 | 61.5% | CN¥1.08 Billion | CN¥1.76 Billion | CN¥1.47 Billion | CN¥385.59 Million | ▼ -3.7 pp |
| 2018 | 65.2% | CN¥1.11 Billion | CN¥1.71 Billion | CN¥1.55 Billion | CN¥431.16 Million | ▼ -25.7 pp |
| 2017 | 90.9% | CN¥1.49 Billion | CN¥1.64 Billion | CN¥1.75 Billion | CN¥255.55 Million | ▲ +9.8 pp |
| 2016 | 81.1% | CN¥570.33 Million | CN¥703.35 Million | CN¥896.10 Million | CN¥325.77 Million | ▼ -0.2 pp |
| 2015 | 81.3% | CN¥485.17 Million | CN¥596.76 Million | CN¥754.66 Million | CN¥269.49 Million | ▼ -3.0 pp |
| 2014 | 84.3% | CN¥452.17 Million | CN¥536.59 Million | CN¥714.05 Million | CN¥261.89 Million | ▲ +13.5 pp |
| 2013 | 70.8% | CN¥180.31 Million | CN¥254.64 Million | CN¥363.87 Million | CN¥183.56 Million | — |